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Background: Controversy persists about how effectively empirically-supported treatments for major
depression work in actual clinical practice as well as how patients choose among them. We examined
the acute phase effectiveness of cognitive therapy (CT), interpersonal psychotherapy (IPT), and
combined psychotherapy–pharmacotherapy (PHT) in a naturalistic setting, allowing patients their
choice of treatment.
Methods: The study compared CT (n¼63), IPT (n¼56), CT–PHT (n¼34), and IPT-PHT (n¼21) for 174
subjects with major depression in a secondary care mood disorders clinic. Patient preference, rather
than randomization, determined treatment selection. The Beck Depression Inventory-II (BDI) was the
primary outcome variable. Exclusion criteria were minimal.
Results: All treatments were associated with a reduction in depressive symptoms, with a 35% remission
rate by week 26. Overall improvement was well within ranges reported in efﬁcacy trials. On average,
treatment effects of the different interventions straddled the same range, but moderation analyses
revealed that BDI scores dropped faster in the ﬁrst 16 weeks in patients who received CT alone than
patients who received CT and pharmacotherapy, a pattern not found in patients who received IPT (with
or without pharmacotherapy).
Limitations: Limitations consist of a modest sample size, choice of treatment was made by participants
which may have been inﬂuenced by many sources, and the absence of a non-active control group.
Conclusions: This study supports the effectiveness of empirically-supported antidepressant treatments
selected by patients in routine settings, and provides an indication that speed of therapeutic response
may vary amongst treatments.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Current treatment guidelines rely heavily on the results of
randomized controlled trials (RCTs) of treatment efﬁcacy. Based
on the results of such trials, guidelines for major depressive
disorder (MDD) call for ﬁrst line application of pharmacotherapy
(PHT) or time-limited psychotherapies like cognitive therapy (CT)
or interpersonal psychotherapy (IPT), which possess the bestll rights reserved.
Neuropsychology, University
, The Netherlands.
(F. Peeters).
., The clinical effectiveness o
isorders (2012), http://dx.ddocumented efﬁcacy for acute phase treatment of MDD in
secondary care settings (APA, 2010; Lam et al., 2009; Parikh
et al., 2009).
Yet for over a decade, concerns have been expressed about the
utility of generalizing the results of such efﬁcacy studies to daily
clinical practice. This may partially explain the gap between
science and daily practice in depression treatment (Gonzalez
et al., 2010; Shafran et al., 2009; Young et al., 2001). Researchers
and clinicians have questioned whether depressed patients
fare as well in ‘‘real life’’ treatment outside a highly controlled
study (effectiveness). Several considerations underlie this concern
(Goldfried and Wolfe, 1998; Westen et al., 2004). First, real life
patients participate in the process of choosing type of treatment,f evidence-based interventions for depression: A pragmatic trial
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and satisfying their treatment preference (Corrigan and Salzer,
2003; Seligman, 1995). The absence of choice may reduce external
validity of RCTs, although recent evidence is equivocal about this
claim (Hegerl et al., 2010; Kendrick et al., 2006; Kocsis et al., 2009;
Leykin et al., 2007; Raue et al., 2009). Second, participants
volunteering in RCTs may not be representative of the self-
declared patients seeking treatment in routine daily practice
because of differing clinical characteristics (e.g., severity and
duration of current episode, comorbidity), many exclusion criteria,
and willingness to be randomized (Stirman et al., 2005;
Wisniewski et al., 2009; Zimmerman et al., 2005). Third, treat-
ments within the context of a RCT are highly controlled in content,
duration, number of sessions, therapist qualiﬁcations, and patient
choice, complicating translation to real-world clinical practice
(Cuijpers et al., 2010b; Shadish et al., 2000; Shadish et al., 1997).
Finally, doubts have been expressed about reported efﬁcacy of
empirically-supported therapies (ESTs) in the light of evidence for
publication bias; real efﬁcacy ﬁgures may be lower than previously
reported (Cuijpers et al., 2010a; Turner et al., 2008).
Consequently, there have been calls for research to address the
effectiveness rather than efﬁcacy of the ESTs for MDD in natur-
alistic treatment settings (March et al., 2005; Tunis et al., 2003).
This translational research aims to convert the results from
clinical studies into everyday clinical practice (Sullivan and
Goldmann, 2011; Woolf, 2008).
Recently, some studies have examined the effectiveness of
treatment-as-usual (TAU) in large clinical samples and compared
them to the efﬁcacy of the same treatments in clinical trials
(Barkham et al., 2008; Cuffel et al., 2003; Minami et al., 2008;
Shadish et al., 2000; Stiles et al., 2008; van der Lem et al., 2011).
Although most of these studies seem to show that TAU overall
retains the beneﬁts of ESTs observed in clinical trials, methodo-
logical limitations hinder reliable interpretation of their results.
Drawbacks of these studies include the largely unknown char-
acteristics of the provided treatments, the large number of
missing cases, and the use of unreliable diagnostic categories
and outcome measures (Clark et al., 2008). Studies examining
the effectiveness of ESTs in routine daily practice are scarce.
Additionally, most of these studies suffers from methodological
limitations like absence of well-validated diagnostic procedures,
uncertainty about therapists’ training and treatment integrity, or
lack of control of the use of concurrent psychotropic medication.
However, there are some indications that IPT may be effective
outside RCT settings (Markowitz et al., 2009), and that the
effectiveness of CT is almost comparable to its reported efﬁcacy
(Gibbons et al., 2011; Merrill et al., 2003; Persons et al., 1999;
Schindler et al., 2011; Westbrook and Kirk, 2005). The effective-
ness of community PHT in comparison to efﬁcacy estimates varies
widely among studies (Rush et al., 2004; Wisniewski et al., 2009).
To date, no studies have investigated the effectiveness of these
ESTs, alone or in combination, delivered at one site by the same
team of therapists in a secondary care, integrated mood disorders
treatment setting in which formally diagnosed patients with
MDD, who actively seek treatment, could freely choose among
treatment options.
The present study examined the effectiveness of IPT and CT
(each alone and combined with antidepressant medication) in
patients with a well-classiﬁed of MDD episode actively seeking
treatment in an outpatient treatment facility. From the outset,
our purpose was to test the effectiveness of the treatments
as administered in routine daily practice under clinically repre-
sentative conditions (Shadish et al., 2000). As already stated,
patient preference for a treatment may enhance outcome. As
RCTs by deﬁnition prevent patients from choosing their preferred
treatment, we did not randomize but followed the patients’Please cite this article as: Peeters, F., et al., The clinical effectiveness o
in routine practice. Journal of Affective Disorders (2012), http://dx.dpreference in treatment allocation. We hypothesized that the
effectiveness of treatments would be comparable to the outcome
typically found in RCTs. Thus, this is, to our knowledge, the ﬁrst
study to examine the comparative effectiveness of freely chosen,
empirically supported antidepressant treatments in a naturalistic
setting.2. Methods
2.1. Design
We conducted a controlled treatment study with a 26-week
follow-up. Length of acute treatment depended on achieving
remission and varied accordingly between 6 and 26 weeks. Some
treatments lasted longer than 26 weeks due to treatment-resis-
tance; these patients were included in the present analysis. In this
naturalistic treatment setting, patient preference determined
treatment allocation. This report closely follows the guideline
for reporting pragmatic trials recently published by Zwarenstein
et al. (2008).2.2. Participants
Data were collected from depressed patients seeking treat-
ment at the mood disorders treatment program of an outpatient
mental health care center (RIAGG Maastricht) in Maastricht, the
Netherlands. This secondary care facility treats individuals aged
18–65 years with varied psychiatric disorders referred by other
health professionals (e.g., general practitioners and social work-
ers). Health insurance companies cover the entire cost of treat-
ments at the center. After initial screening, patients are assigned
to specialized treatment programs for further diagnostic inter-
viewing and treatment. In the mood disorders program,
depressed individuals are preferentially being treated with CT,
IPT, or a combination of CT–PHT or IPT–PHT.
The only inclusion criterion was a primary diagnosis of non-
delusional major depressive disorder (MDD) determined with the
Structured Clinical Interview for DSM-IV Axis I (SCID-I: First et al.,
1995). Trained masters or doctoral-level psychologists, psy-
chotherapists, psychiatrists, and senior psychiatric residents
(supervised by psychiatrists with a minimum of 5 years clinical
experience) administered the SCID-I, which compromises a rou-
tine part of the diagnostic procedure in the mood disorders
program. Inter-rater reliability of the SCID-I was not assessed.
The only exclusion criteria at entry were primary diagnoses other
than MDD (e.g., bipolar disorder, psychotic disorder, or substance
abuse), high acute suicide risk, and insufﬁcient ﬂuency in Dutch.
Comorbid secondary Axis I diagnoses like anxiety disorders or
substance abuse were permitted.
The Ethics Committee of Maastricht University approved the
study. All participants provided written informed consent. Of all
eligible individuals referred to the mood disorders treatment
program, 65% agreed to participate in the study. No information
about baseline characteristics of the non-participants is available,
which prevents comparing them with study participants.2.3. Treatments
2.3.1. Cognitive therapy
Licensed psychologists and psychotherapists provided CT. Their CT
experience ranged from 1 to 12 years at study onset. Three therapists
are faculty who teach post-graduate courses in CT. All therapists
received appropriate training and followed the procedures outlined inf evidence-based interventions for depression: A pragmatic trial
oi.org/10.1016/j.jad.2012.08.022
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Sessions typically lasted 50min weekly, with the possibility of
fortnightly booster sessions in later stages. CT therapists reviewed
ongoing cases and addressed difﬁculties encountered during therapy
in weekly 60min sessions.2.3.2. Interpersonal psychotherapy
Licensed psychologists, psychotherapists, and psychiatrists
with IPT experience of between 1 and 10 years at the beginning
of the study provided IPT, based on the manual by Klerman et al.
(1984). Three therapists are faculty in post-graduate IPT courses.
All therapists received appropriate training. As in CT, sessions
were held for 50 min weekly with the possibility of maintenance
sessions following the acute phase treatment. IPT therapists also
convened for an hour weekly to review ongoing cases.2.3.3. Pharmacotherapy
Participants in the combined treatment conditions received
some additional PHT sessions. These sessions typically lasted
15 min and focused on medication management (biochemical
rationale, discussion of adverse events, dosage adjustment), and
management of the participants’ functioning (assessing function-
ing in major life spheres). Application of techniques and strategies
speciﬁc to CT or IPT was neither encouraged nor strictly prohib-
ited. Participants generally received a serotonin reuptake inhibi-
tor (SSRI) following national and international guidelines. In case
of SSRI non-response in the current episode, participants were
prescribed another SSRI, venlafaxine or a tricyclic agent augmen-
ted with lithium in case of subsequent non-response.2.4. Procedures and outcomes
During the diagnostic work-up, consisting of an open inter-
view and the SCID-I, patients received verbal and written infor-
mation about treatment options in the mood disorders program.
Patients were explicitly informed that CT and IPT are time-limited,
empirically validated therapies lasting a maximum of 15–20 sessions.
After this work-up, a multidisciplinary team meeting, brieﬂy discuss-
ing clinical history and diagnosis, yielded a treatment recommenda-
tion. As is typical in Dutch treatment settings, the ﬁnal choice of
treatment was made by patient and therapist agreement, but
predominantly guided by patient preference. Following the diagnostic
work-up, staff provided comprehensive information on the study
procedure, asked patients to participate, and obtained written
informed consent.Table 1
Demographic and clinical characteristics of subjects entering treatment (n¼174).
CT (n¼63)
Female, n (%) 38 (60)
Age in years, M (sd)nn 42 (11)
Spouse (%) 32 (50)
At work, n (%) 23 (37)
BDI, M (SD) 25.5 (9.7)
SCL-90 total score, M (SD) 219 (56)
Axis I diagnosis, n (%)
MDD, ﬁrst episode 28 (44)
MDD, recurrent 35 (56)
Axis I comorbidity, n (%) 30 (46)
Duration current episode 424 months, n (%) 27 (44)
Note: CT¼cognitive therapy, CT–PHT¼cognitive therapy and pharmacotherapy,
pharmacotherapy.
nn po0.01.
Please cite this article as: Peeters, F., et al., The clinical effectiveness o
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Measures were administered prior to treatment and at 8, 16,
and 26 weeks. The main outcome variable was the Beck Depres-
sion Inventory Second Edition BDI-II (Beck et al., 1996). The BDI
measures depressive severity, with higher scores indicating more
severe depression (range 0–63). Its construct validity and relia-
bility have consistent support in varied samples (Beck et al.,
1996). Using the guidelines of Jacobson and Truax (1991),
response was deﬁned a priori as a decrease of at least 10 points
from baseline BDI-score, whereas remission was deﬁned as an
absolute BDI-score of 10 points or less. General psychopathology
(i.e., overall emotional dysfunction) was measured at baseline
with the Symptom Check-List 90 (SCL-90), with a score range
from 90 (asymptomatic) to 450 (severe psychopathology).
The SCL-90 has high reliability and research supports its validity
(Derogatis et al., 1976). The SCID-I assessed Axis I diagnoses. Other
baseline measures included sex, age, marital status, employment,
and the duration of the current depressive episode.2.6. Data analysis
Comparisons of demographic- and baseline-characteristics and
differences between treatment groups were done with w2 tests for
categorical data and ANOVAs for quantitative data. Effect sizes
were calculated using Cohen’s D (mean_0 weeks–mean_26
weeks/pooled SD), only with patients whose data were available
at 26 weeks. The effectiveness of the different treatments was
tested with mixed linear regression modeling, using maximum
likelihood estimation in SPSS (version, 18.0). The mixed model
had three levels: therapists, patients and measurements (time at
0, 8, 16, 26 weeks). The inﬂuence of the therapists’ level was
analyzed, but since there were too many therapists in this study,
resulting in too small nested patient clusters per therapist, this
level was omitted from further analyses. Patient effects were
included by choosing an unstructured covariance matrix for the
repeated measures, which is the most general structure.
The dependent variable in the analysis was the BDI (measured
at 0, 8, 16, 26 weeks). Intervention was represented by two
dummy variables: CT vs IPT (CT¼1, IPT¼0) and psychotherapy
alone vs psychotherapy combined with PHT (PSY vs COM;
psychotherapy alone¼1, combination treatment¼0).
First, we ﬁtted the growth curve for time. It emerged that the
best ﬁt was not provided by a linear model (time), but by a
polynomial model (time and time2) instead. We then built a full-
saturated model, with the main effects of time, time2, CT vs IPT,CT–PHT (n¼34) IPT (n¼56) IPT-PHT (n¼21)
19 (55) 32 (57) 16 (76)
36 (13) 41 (12) 45 (11)
16 (47) 28 (50) 11 (52)
14 (41) 17 (30) 7 (33)
24.8 (8.9) 22.1 (9.5) 27.1 (9.6)
217 (61) 203 (49) 230 (63)
14 (41) 26 (46) 10 (47)
20 (59) 30 (54) 11 (53)
19 (55) 26 (46) 9 (43)
15 (44) 29 (52) 9 (41)
IPT¼ interpersonal psychotherapy, IPT–PHT¼ interpersonal psychotherapy and
f evidence-based interventions for depression: A pragmatic trial
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variables. Non-signiﬁcant interaction effects were hierarchically
excluded from the model until only signiﬁcant terms remained
(using a¼0.05, two-tailed). Treatment group differences were
made ‘visible’ in plots of predicted values using SPSS Graphs.
Initially we included a selection of potential confounders as
covariates in the saturated model. Since adjustment for confounds
did not affect the results, we excluded them from the present
analysis for ease of interpretation.3. Results
The study sample compromised 174 participants. Table 1
summarizes their demographic and clinical characteristics,
grouped by treatment. There was a signiﬁcant difference in age
between the groups, with CT–PHT participants being somewhat
younger, but adjustment for age did not affect the outcome
results. Other baseline characteristics between the treatment
groups were not signiﬁcantly different. Of participants, 103
(59%) were female. Mean age in the total group was 42.4
(SD¼11.1), mean baseline BDI was 24.5 (SD¼9.6), mean SCL-90
score was 215.1 (SD¼56.4), and mean duration of the current
episode was 8.2 months (SD¼13.3). Chronic depression (42
years) was diagnosed in 63 (36%) participants, and 92 (53%)
suffered from at least one comorbid axis I diagnosis. Due to the
extensive Dutch social welfare system, in which long-term sick
leave does not have major ﬁnancial consequences, many partici-
pants were not currently working.3.1. Attrition, mean scores, response, and remission
The percentage of participants available for analyses (not lost
to follow-up) at 8, 16, and 26 weeks were 91%, 83%, and 76%
respectively, which is within an acceptable range of attrition. All
available data from all 174 patients were included into the mixed
regression without imputation of missing data and without
dropping any patient.
The mean number of all sessions was 13.5 (S.D.¼6.3) for CT,
17.6 (S.D.¼7.7) for CT–PHT, 14.6 (S.D.¼6.1) for IPT, and 20.1
(S.D.¼8.4) for IPT–PHT. In the combined treatment conditions,
most patients saw different therapists for PHT and psychotherapy,
which may account for the greater number of sessions in these
treatments. Observed mean BDI-scores, attrition and rates of
participants achieving response and remission during follow-up
in the different treatment groups appear in Table 2. No signiﬁcant
differences in attrition, response or remission emerged across
treatments (although there appear to be some meaningful differ-
ences in attrition, especially in respect to the low rate of attrition
in the IPT–PHT group).
Clinical improvement after the ﬁrst 8 weeks of treatment was
modest, yielding remission in 20% of participants. However, BDI
scores decreased steadily thereafter, with an overall remission
rate at 26 weeks in the sample of 35% (of the original 174
patients). Considerable clinical improvement could still be
observed between weeks 16 and 26. Treatment effect sizes were
large (Table 3). Effect sizes of Z0.8 are generally considered large,
effect sizes of 0.5 moderate, and effect sizes of 0.2 small (Cohen,
1988). Table 3 also compares the current remission rates with
estimates based on literature review reported by Keitner et al.
(2006). The remission rates achieved in our study lie well within
the range of those reported in clinical efﬁcacy trials.Please cite this article as: Peeters, F., et al., The clinical effectiveness o
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Table 4 summarizes results from the mixed regression ana-
lyses. The ﬁnal model displays a moderating effect of the different
treatment conditions and time. As these cannot be interpreted
from the regression model only, we investigated the shape and
direction of the moderation in subsequent subgroup analyses,
depicted in Fig. 1a and b.
As Fig. 1a illustrates, the drop in BDI scores of those patients
who received IPT only and IPT in combination with an antide-
pressant appeared to have a parallel development, although those
who received combination treatment started out and ended up
with higher BDI scores, a difference between the two groups that
remained almost stable in the course of treatment. However, in
the cognitive therapy group (Fig. 1B), BDI scores appeared to drop
much faster in patients who received only CT compared to those
receiving CT–PHT. Despite this difference, both groups (CT and
CT–PHT) started out and ended up around the same BDI mean.
This indicates that it is the differential rate of response of those
receiving CT vs those receiving CT–PHT (and the absence of such a
differential rate in the IPT group) that explains the moderation
effect of CT vs IPT we found. Residuals were checked, but our
results could not be explained by outliers or non-normality.4. Discussion
This study examined the effectiveness of ESTs for MDD in a
naturalistic setting. Participants were self-declared patients seek-
ing treatment in a ‘real world’ mental health setting and suffering
from moderately severe depression, considerable rates of chroni-
city and recurrence, and high rates of Axis I comorbidity. Treat-
ment assignment was not random but, reﬂecting daily practice in
the Netherlands, guided by patient preferences. With a paucity of
exclusion criteria, our study included participants who would
have been refused by many efﬁcacy trials (Stirman et al., 2005;
Wisniewski et al., 2009; Zimmerman et al., 2005), which should
make its results more generalizable to routine clinical practice.
The overall remission (35%) rate after 26 weeks was considerable,
within the range of reported within RCT efﬁcacy contexts (Keitner
et al., 2006), and comparable to most naturalistic studies (Barkham
et al., 2008; Cuffel et al., 2003; Minami et al., 2008; Shadish et al.,
2000; Stiles et al., 2008; Trivedi et al., 2006). The effect sizes in our
study are somewhat larger than reported in recent meta-analyses
(Cuijpers et al., 2008, 2011a, 2011b). All treatment groups also
generated effect sizes reliably greater (d’sZ1.0, Table 3) than natural
course benchmarks (d¼0.15) for MDD (Minami et al., 2007).
We observed no difference in overall effectiveness among
treatments either as monotherapies or in combination. This
accords with what in psychotherapy has become known as the
‘dodo-bird verdict’: the persistent ﬁnding that psychotherapies
for MDD exhibit similar efﬁcacy (Cuijpers et al., 2008; Luborsky,
1995; Wampold et al., 1997). Moreover, it jibes with recent, but
not all meta-analyses that reported no overall differences in
efﬁcacy between monotherapy and combination therapy in mod-
erately severe, non-chronic MDD (Cuijpers et al., 2008, 2011a; de
Maat et al., 2007; Friedman et al., 2004; Pampallona et al., 2004).
Surprisingly, a moderation analysis showed that BDI-scores in
patients receiving CT alone, although ending around the same
mean, decreased faster than these scores in patients receiving CT
combined with antidepressant medication. This moderation was
not seen in IPT vs IPT–PHT. One can speculate that differences
between CT and CT–PHT in (1) therapeutic alliance, (2) adherence
to and engagement with therapeutic techniques by therapist and/
or patient, and/or (3) unknown patient characteristics are asso-
ciated with this difference in time path (DeRubeis et al., 2005).f evidence-based interventions for depression: A pragmatic trial
oi.org/10.1016/j.jad.2012.08.022
Table 2
Observed mean (S.D.) BDI-scores and number (%) of depressed patients lost to follow-up and achieving response and remission during treatment.
Time point CT CT–PHT IPT IPT–PHT Overall
BDI 8 weeks 18.2 (11.2) 20.4 (10.3) 17.2 (9.8) 21.8 (12.1) 18.7 (10.7)
16 weeks 14.2 (9.9) 18.0 (11.6) 14.3 (9.8) 18.9 (10.6) 15.6 (10.4)
26 weeks 12.9 (11.3) 14.7 (11.3) 9.9 (8.3) 16.3 (10.7) 12.9 (10.6)
Attrition 8 weeks 7 (11) 6 (17) 3 (5) 0 (0) 16 (9)
16 weeks 15 (23) 6 (17) 7 (12) 3 (14) 31 (17)
26 weeks 18 (28) 7 (20) 16 (28) 1 (4) 42 (24)
Response 8 weeks 19 (30) 7 (20) 14 (25) 5 (24) 45 (26)
16 weeks 23 (36) 10 (29) 17 (30) 6 (28) 56 (32)
26 weeks 26 (41) 12 (35) 22 (39) 7 (33) 67 (39)
Remission 8 weeks 13 (21) 5 (15) 13 (23) 3 (14) 34 (20)
16 weeks 18 (29) 5 (15) 15 (27) 3 (14) 41 (24)
26 weeks 23 (37) 10 (29) 20 (36) 7 (33) 60 (35)
Note: CT¼cognitive therapy, CT–PHT¼cognitive therapy and pharmacotherapy, IPT¼ interpersonal psychotherapy, IPT–PHT¼ interpersonal psychotherapy and pharma-
cotherapy. Attrition is the number (%) of participants lost to follow-up (BDI-scores). Response was deﬁned as a decrease of at least 10 points from baseline BDI-score,
remission was deﬁned as an absolute BDI-score of 10 points or less. Remission and response rates were based on available data only, without imputation of missing data.
Table 3
Effect sizes of EST and remission rates in comparison to RCT evidence base (based
on Keitner et al. (2006)).
Effect size Remission (%)
Current study RCTs
CT 1.3 37 30–48
CT–PHT 1.0 29 16–40
IPT 1.5 36 30–48
IPT–PHT 1.0 33 16–40
Note: CT¼cognitive therapy, CT–PHT¼cognitive therapy and pharmacotherapy,
IPT¼ interpersonal psychotherapy, IPT–PHT¼ interpersonal psychotherapy and
pharmacotherapy.
Table 4
Effects of cognitive therapy vs interpersonal therapy and psychotherapy alone vs
combination treatment of psychotherapy and antidepressant medication on
depressive symptoms (BDI) in the course of 26 weeks.
Variable ß S.E. p
Intercept 22.25 1.22
Time 4.61 1.26 o0.001
Time2 0.31 0.39 0.440
CT vs IPT 3.33 1.69 0.052
PSY vs COM 4.84 2.37 0.043
CT vs IPT  Time 4.00 1.76 0.024
CT vs IPT  Time2 1.17 0.54 0.034
PSY vs COM  Time 1.51 2.42 0.533
PSY vs COM  Time2 0.61 0.74 0.406
CT vs IPT  PSY vs COM 5.43 3.11 0.082
CT vs IPT  PSY vs COM  Time 6.59 3.19 0.041
CT vs IPT  PSY vs COM  Time2 2.09 0.97 0.033
Note: time¼0, 8, 16, 26 week measurement (coded in the regression analyses as 0,
1, 2, 3, respectively).
CT vs IPT¼Cognitive Therapy (1) vs Interpersonal Therapy (0).
PSY vs COM¼Psychotherapy alone (1) vs Combination treatment of psychotherapy
and Antidepressant medication (0).
Fig. 1. (a) Effects of psychotherapy alone vs combination treatment in the IPT-group.
(b) Effects of psychotherapy alone vs combination treatment in the CT-group.
F. Peeters et al. / Journal of Affective Disorders ] (]]]]) ]]]–]]] 5Only a minority (20%) of patients remitted through 8 weeks of
treatment; between weeks 8 and 26 many participants reported
further improvement. As in the STAR*D study (Trivedi et al., 2006),
which investigated serial treatment of MDD with the SSRI citalopram
as the initial step, patients in the real clinical world seem to achieve
signiﬁcant clinical improvements more slowly than typically assessed
in RCTs. These results seem to justify a longer treatment duration
aimed at response and remission than most manuals, textbooks,
and guidelines describe. We can only hypothesize possible reasons for
this different treatment time frame. Possibilities include a lowerPlease cite this article as: Peeters, F., et al., The clinical effectiveness o
in routine practice. Journal of Affective Disorders (2012), http://dx.dtreatment adherence by therapists or patients, the absence of the
ﬁxed time limit employed in RCTs that pressures patients and
therapists to work fast, or unknown participant characteristics.f evidence-based interventions for depression: A pragmatic trial
oi.org/10.1016/j.jad.2012.08.022
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be noted that the vast majority of participants preferred psy-
chotherapy alone, while a smaller group chose the combination of
psychotherapy and PHT. This corroborates earlier reports on
treatment preference by individuals seeking treatment for MDD
(Kessing et al., 2005; Raue et al., 2009; van Schaik et al., 2004).
Congruence between the treatment patients prefer and the
treatment they actually receive is generally considered as a
positive prognostic indicator of outcome (Raue et al., 2009). Given
the low compliance rates in pharmacotherapy treatment of
depression (Vergouwen et al., 2003) this suggests the need for
wider availability of evidence-based psychotherapies for MDD in
routine clinical practice. Although ‘routine clinical practice’ may
differ considerably across settings, cultures and health care
systems, our results may inform both clinicians and decision
makers even in contexts that do not offer the array of available
treatments available in our center. Doubts about generalizability
of efﬁcacy data, and cultural and socioeconomic factors appear to
discourage implementation and availability of ESTs for MDD
(Mojtabai, 2009). Despite patient treatment preference and cur-
rent empirical data like that presented in this study, pharmaco-
logical treatment predominates (Marcus and Olfson, 2010; Olfson
and Marcus, 2010) and many depressed patients remain under-
treated (Gonzalez et al., 2010).
This study has both limitations and strengths. First, the some-
what modest sample size may have obscured signiﬁcant differ-
ences in effectiveness between treatments. Second, 35% of eligible
patients referred to the mood disorders treatment program chose
not to participate in the study which may hamper generalization.
Additionally, as in other naturalistic studies (Rush et al., 2006),
a substantial number of participants were lost to follow-up.
We addressed the latter problem by the use of mixed linear
regression modeling. Third, inherent in our pragmatic design,
participants were not randomized. Treatment choice depended on
participants’ preferences, which may have been inﬂuenced by
many sources. Fourth, the absence of a non-active control group
raises uncertainty about whether the observed improvement
indicates ESTs in our setting were effective. Natural history might
conceivably account for the sample’s symptomatic improvement.
We deem this unlikely, in as much as the mean duration of
current episode in our sample was more than 8 months, and more
than a third suffered from chronic MDD (42 years). Rates of
spontaneous improvement and remission decline considerably
once an episode of MDD surpasses 6 months (Spijker et al., 2002).
Additionally, the treatment effect sizes were substantially larger
than natural history benchmarks for MDD. Fifth, treatments were
delivered as usual in our treatment program. Although therapists
were encouraged to adhere to published manuals (Beck et al.,
1979; Klerman et al., 1984), we did not monitor treatment
integrity, content, and quality beyond the weekly therapist meet-
ings that reviewed ongoing cases. Thus differences in quality of
therapy and therapists might have inﬂuenced results. However,
we consider this unlikely, as therapies followed treatment man-
uals, therapists were adequately trained to deliver treatments,
and inexperienced and experienced therapists were equally
divided across the different ESTs.
The study’s main strength is its realism: it examined the
effectiveness of ESTs for MDD as they are delivered in daily
practice to the people who actively seek psychiatric treatment.
A structured diagnostic interview ensured accurate classiﬁcation
of patients’ diagnoses, and well-deﬁned, well-administered ther-
apeutic approaches were assessed with a psychometrically robust
outcome measure. Further, unlike RCTs, our study assessed
patients assigned to an empirically supported treatment of their
choice. To our knowledge, this is the ﬁrst naturalistic study to
examine the effectiveness of CT, IPT, and their combination withPlease cite this article as: Peeters, F., et al., The clinical effectiveness o
in routine practice. Journal of Affective Disorders (2012), http://dx.dantidepressant medication in the treatment of MDD. No accepted
standards exist for reporting the results of a pragmatic trial like
ours. To maximize the applicability of our results, we followed
recent guidelines to describe setting, interventions, therapists,
participants, and outcomes (Zwarenstein et al., 2008).
Because of differences in key variables (e.g., setting, patients),
no single naturalistic study of antidepressant treatments can
deﬁnitively determine their effectiveness. More effectiveness
studies, together with efﬁcacy trials, are needed to fully explore
the magnitude of our therapeutic abilities.Role of funding source
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